Plasma Derived Medicine Market Size, Growth and Forecast 2032

Market Overview

The global Plasma Derived Medicine Market is projected to grow from USD 18,493.00 million in 2024 to an estimated USD 31,774.41 million by 2032, reflecting a compound annual growth rate (CAGR) of 7.00% from 2025 to 2032. This growth is driven by the increasing demand for immunoglobulins, clotting factors, and albumin, essential for treating various immunodeficiency disorders, bleeding disorders, and critical care conditions.

Key market drivers include the rising prevalence of chronic diseases, advancements in plasma collection and processing technologies, and a growing emphasis on developing innovative therapies. Additionally, the expanding geriatric population and improved healthcare infrastructure in emerging markets contribute to the market's expansion.

Geographically, North America leads the market due to a well-established healthcare system and high demand for plasma-derived therapies. Europe and the Asia Pacific regions are also significant contributors, with increasing investments in healthcare infrastructure and rising patient awareness. Key players in the market include CSL Limited, Grifols S.A., Octapharma AG, Kedrion S.p.A., and LFB Group, all of which play pivotal roles in advancing plasma-derived therapies and expanding global access.

Market Insights

• The global plasma-derived medicine market is projected to grow from USD 18,493.00 million in 2024 to USD 31,774.41 million by 2032, with a CAGR of 7.00% from 2025 to 2032.
• Key drivers include the increasing prevalence of chronic diseases, advancements in plasma collection and processing technologies, and rising demand for immunoglobulins and clotting factors.
• The expanding elderly population globally is contributing to the increased demand for plasma-derived therapies, especially for immunodeficiency disorders.
• The primary restraint is the dependence on plasma donations, with supply limitations and high costs of collection and processing.
• Stringent regulations and the complex approval process for new plasma-derived therapies can slow market growth and increase time-to-market for new products.
• North America holds the largest market share, driven by a well-established healthcare system and high demand for plasma-derived therapies.
• Emerging markets, especially in Asia-Pacific and Latin America, are experiencing significant growth due to improved healthcare infrastructure and rising disease awareness.

Market Drivers

Expansion of Healthcare Infrastructure in Emerging Markets

The development and expansion of healthcare infrastructure in emerging markets play a critical role in driving the demand for plasma-derived medicines. Rapid urbanization, increased healthcare expenditure, and improvements in healthcare access are creating more opportunities for the distribution and adoption of advanced medical treatments, including plasma-derived therapies. As healthcare systems improve in regions such as Asia-Pacific, Latin America, and the Middle East, there is greater availability and affordability of these therapies. Increased awareness among healthcare professionals and patients regarding the benefits of plasma-derived medicines is also a contributing factor to the growing market demand. Furthermore, many governments in these regions are implementing initiatives to enhance blood and plasma donation programs, which in turn support the development of plasma-derived therapies. This is especially important as the availability of donated plasma is a key factor in meeting market demand.

Growing Investment in Research and Development

The continuous investment in research and development (R&D) by pharmaceutical companies is another key driver for the global plasma-derived medicine market. R&D initiatives are focused on discovering new therapies, improving existing plasma-derived medicines, and expanding indications for treatment. For instance, researchers are exploring the potential of plasma-derived products in treating a wider range of autoimmune diseases, cancers, and other complex disorders. In addition to therapeutic innovation, R&D is also targeting the improvement of production processes and the development of more efficient and cost-effective manufacturing techniques. This ongoing innovation not only broadens the scope of applications for plasma-derived products but also strengthens their efficacy and safety profiles, fostering increased adoption. Additionally, with the rise in patient-centric care models and personalized medicine, R&D is increasingly focused on tailoring plasma-derived treatments to individual patient needs, improving outcomes and reducing side effects. As pharmaceutical companies continue to invest in these advancements, the market for plasma-derived medicines is expected to experience sustained growth.

Increasing Prevalence of Chronic Diseases and Immunodeficiency Disorders 

The rising global incidence of chronic diseases, including autoimmune disorders, hemophilia, and immunodeficiency disorders, significantly drives the demand for plasma-derived medicines. Plasma-derived therapies, such as immunoglobulins and clotting factors, are essential in managing these conditions. For instance, a report by the World Health Organization (WHO) highlights the increasing prevalence of immunodeficiency disorders, emphasizing the critical role of immunoglobulin therapies in reducing infection rates and improving patient outcomes. Additionally, studies conducted by the National Hemophilia Foundation underscore the reliance of hemophilia patients on plasma-derived clotting factors to manage bleeding episodes effectively. Immunodeficiency disorders, including primary and secondary immunodeficiencies, lead to a compromised immune system, increasing susceptibility to infections and requiring lifelong treatment with immunoglobulins. Furthermore, advancements in medical research, as noted by the International Plasma Fractionation Association, have improved the efficacy and safety of plasma-derived therapies, making them indispensable for managing chronic conditions. As these conditions become more prevalent, particularly in the aging population, the demand for plasma-derived products is expected to rise accordingly.

Advancements in Plasma Collection and Processing Technologies 

Technological advancements in plasma collection and processing techniques have revolutionized the efficiency and scalability of plasma-derived medicines. For instance, reports from the Plasma Protein Therapeutics Association (PPTA) highlight the adoption of automated plasma collection systems that ensure donor safety while increasing plasma yield. Improved collection methods, such as high-throughput techniques, have made it easier to obtain high-quality plasma while maintaining donor safety. Additionally, innovations in fractionation processes, as documented by the European Medicines Agency (EMA), allow for better extraction and purification of plasma proteins, enhancing the quality and yield of plasma-derived therapies. These advancements have enabled manufacturers to produce consistent and reliable plasma-derived medicines, meeting the growing demand for these life-saving products. Moreover, advancements in freeze-drying and storage techniques, as noted in government health reports, further extend the shelf life of plasma-derived medicines, making them more accessible to patients globally, even in remote areas with limited access to refrigeration. These technological innovations continue to drive the growth and accessibility of plasma-derived therapies worldwide.

Market Trends

Innovation in Fractionation and Plasma Processing Technologies

Innovation in plasma fractionation and processing technologies continues to be a key trend driving the plasma-derived medicine market. Plasma fractionation is the process by which plasma is separated into its individual components to isolate specific proteins required for therapeutic use, such as immunoglobulin, clotting factors, and albumin. Over the years, advances in fractionation technologies have resulted in more efficient and scalable production methods, leading to better quality and higher yields of plasma-derived medicines.Recent innovations in this area include the development of new fractionation techniques, such as the use of chromatography and more efficient filtration methods. These advancements improve the purity and potency of plasma-derived proteins while reducing the risk of contamination. Furthermore, companies are investing in automation and continuous fractionation processes, which reduce the reliance on traditional batch processing, resulting in greater efficiency and reduced costs. Automation in plasma processing also minimizes human error and allows for more consistent production, contributing to a more reliable and sustainable supply of plasma-derived medicines.Additionally, efforts to improve plasma collection and storage methods are part of the overall trend toward enhancing the efficiency and safety of plasma-derived therapies. Plasma collection centers are implementing better screening and testing protocols, while improvements in the storage and transport of plasma have extended its shelf life, allowing for a more stable supply chain and ensuring that the demand for these critical medicines can be met more effectively.

Expansion of Plasma-Derived Therapies in Emerging Markets

The growing presence of plasma-derived therapies in emerging markets is another significant trend in the global market. Regions such as Asia-Pacific, Latin America, and the Middle East are witnessing increased adoption of plasma-derived medicines due to improvements in healthcare infrastructure, growing patient populations, and higher healthcare spending. As more emerging market countries invest in improving healthcare access and services, there is an expanding opportunity for plasma-derived medicine companies to tap into these markets.In countries like China, India, and Brazil, rising healthcare awareness and a surge in the number of patients with chronic conditions and rare diseases are driving the demand for plasma-derived therapies. Governments in these regions are also implementing policies to promote plasma donation and establish more efficient plasma collection systems, which are key to meeting the growing demand for these medicines.Pharmaceutical companies are increasingly investing in partnerships with local healthcare providers and distributors to expand their presence in these regions. Additionally, local production and fractionation facilities are being established to reduce the reliance on imported plasma-derived medicines, which helps make these therapies more affordable and accessible. The growing adoption of plasma-derived therapies in emerging markets is expected to be a key growth driver for the market in the coming years, with many companies focusing on expanding their global footprint to meet the rising demand in these regions.

Rise in Personalized Medicine and Tailored Therapies 

One of the most significant trends currently shaping the global plasma-derived medicine market is the growing focus on personalized medicine and tailored therapies. This trend reflects a broader shift in the healthcare industry toward treatments that are customized to the genetic profile and individual needs of patients. Plasma-derived therapies, such as immunoglobulins, clotting factors, and albumin, are increasingly being adapted to specific patient profiles to improve efficacy and minimize adverse effects. For instance, reports from leading pharmaceutical companies highlight the development of immunoglobulin therapies tailored to address varying levels of immune deficiencies, ensuring patients receive the most effective treatment for their unique conditions. Additionally, government health agencies have emphasized the importance of genetic testing and diagnostics in enabling healthcare providers to design precise therapies for chronic and autoimmune disorders. This shift towards personalized treatments not only enhances therapeutic outcomes but also ensures that patients receive plasma-derived medicines that align with their specific medical needs. Furthermore, advancements in drug delivery systems, such as subcutaneous immunoglobulin (SCIg) therapies, are offering patients greater control over their treatment, improving convenience and quality of life for those undergoing long-term care.

Increased Focus on Home Infusion Therapy 

Another important trend in the plasma-derived medicine market is the rising adoption of home infusion therapy. Traditionally, plasma-derived therapies such as immunoglobulin (IgG) infusions and clotting factor treatments required patients to visit healthcare facilities or clinics for administration. However, as more patients seek convenience and flexibility, there has been a growing trend towards home infusion therapies. For instance, surveys conducted by healthcare organizations reveal that patients with chronic conditions, such as primary immunodeficiency (PID), are increasingly opting for home infusion solutions to reduce the frequency of hospital visits. Pharmaceutical companies have also introduced portable infusion pumps and user-friendly devices, enabling patients or caregivers to administer therapies at home with minimal supervision. Additionally, government-backed initiatives promoting home healthcare services have further accelerated the adoption of this approach, particularly in developed regions. This trend not only improves the quality of life for patients but also reduces the burden on healthcare systems by decreasing hospital admissions. As healthcare providers and pharmaceutical companies continue to focus on patient-centric solutions, home infusion therapy is expected to remain a significant driver of growth in the plasma-derived medicine market, offering patients greater autonomy and better health outcomes.

Market Challenges

High Manufacturing and Product Costs

Another challenge for the plasma-derived medicine market is the high cost associated with the manufacturing and production of plasma-derived therapies. The production of these therapies involves complex, highly specialized processes, such as plasma fractionation and purification, which require sophisticated equipment and highly skilled personnel. Moreover, maintaining quality control, ensuring safety standards, and complying with regulatory requirements add to the operational costs. The process of fractionating plasma into its various components, such as immunoglobulins and clotting factors, also demands considerable time and resources, driving up the cost of the final product.This high manufacturing cost is further compounded by the increasing need for extensive testing and quality assurance procedures to ensure that plasma-derived medicines are safe and effective. For many patients, the high cost of treatment can result in limited access to these life-saving therapies, especially in lower-income regions or countries with inadequate healthcare infrastructure. Furthermore, as healthcare costs continue to rise globally, health insurance coverage and reimbursement policies for plasma-derived medicines become increasingly crucial in determining patient access to treatments. The industry must navigate these financial and logistical challenges to make plasma-derived medicines more affordable and accessible while maintaining the high standards required for patient safety and product efficacy.

Plasma Supply Constraints and Donor Dependency

The global plasma-derived medicine market faces significant challenges due to its dependency on plasma donations. Plasma, the essential raw material for producing therapies like immunoglobulins, clotting factors, and albumin, is collected exclusively from human donors. This reliance creates a persistent supply challenge, especially as global demand for plasma-derived products continues to rise. The process of collecting, testing, and processing plasma is highly regulated and time-intensive, limiting the volume of plasma that can be sourced. Additionally, fluctuations in donor availability and collection rates, influenced by factors such as regulatory constraints, public awareness, and economic conditions, can disrupt the supply chain.For instance, surveys conducted by industry organizations and government authorities highlight the challenges faced by plasma collection centers in maintaining consistent donor participation. These surveys reveal that centers are investing in advanced donor recruitment strategies and implementing personalized plasmapheresis programs to optimize donation volumes without compromising donor safety. Furthermore, efforts to enhance collection infrastructure and streamline logistics are being prioritized to address regional disparities in plasma donation rates. These initiatives underscore the importance of innovation in improving collection practices and exploring alternatives to traditional donation methods. By addressing these supply constraints, the market aims to ensure the availability of life-saving treatments globally.

Market Opportunities

Expansion in Emerging Markets

A significant market opportunity for plasma-derived medicines lies in the expansion into emerging markets, such as Asia-Pacific, Latin America, and the Middle East. These regions are experiencing rapid growth in healthcare infrastructure and increased investments in medical technologies, which are creating a favorable environment for the adoption of advanced therapies, including plasma-derived medicines. The rising incidence of chronic diseases, immunodeficiency disorders, and hemophilia in these regions, coupled with improving healthcare access, is driving the demand for plasma-derived therapies. Additionally, as these markets experience urbanization and rising incomes, there is greater awareness among patients and healthcare providers about the benefits of plasma-derived treatments. Governments in many of these countries are also focusing on improving blood and plasma donation programs, which is expected to further fuel the availability and accessibility of these critical therapies. This growing demand in emerging markets presents a significant opportunity for global players to expand their market presence, forge partnerships, and enhance their distribution networks.

Advancements in Therapeutic Applications

The continuous development of new therapeutic applications for plasma-derived medicines presents another substantial market opportunity. Research into new indications, such as the use of immunoglobulins in autoimmune diseases, rare genetic disorders, and even cancer therapies, is expanding the potential applications for plasma-derived treatments. Additionally, innovations in formulation technologies, such as subcutaneous immunoglobulins (SCIg), are enhancing patient convenience and treatment adherence, which could drive further market growth. As pharmaceutical companies continue to invest in research and development, the creation of novel therapies and formulations is expected to increase the demand for plasma-derived medicines, benefiting both existing and new patient populations. This expansion into new therapeutic areas offers an attractive opportunity for growth and market diversification.

Market Segmentation Analysis

By Product

Immunoglobulins, or antibodies, are among the most widely used plasma-derived medicines, primarily treating immune deficiency diseases, autoimmune disorders, and infections. The increasing prevalence of primary immunodeficiency disorders (PID) and secondary immune deficiencies, especially in aging populations, has led to a rise in the demand for immunoglobulin-based therapies, making it one of the largest segments in the market. Coagulation factor concentrates play a vital role in treating bleeding disorders like hemophilia by replacing missing or deficient clotting factors. As awareness of bleeding disorders increases and early diagnosis becomes more common, the coagulation factor segment continues to grow steadily, driven by the ongoing need for long-term therapy in affected patients. Albumin, a critical protein found in human plasma, is used to treat liver disease, burns, and trauma. The rising prevalence of chronic liver conditions, particularly cirrhosis, is fueling the demand for albumin-based therapies, making it a key segment in the plasma-derived medicine market. Other plasma-derived medicines include therapies for rare conditions such as Alpha-1 Antitrypsin Deficiency (AATD) and Hereditary Angioedema (HAE). Though these therapies represent a smaller portion of the market, their demand is growing as awareness and treatment advancements for these rare conditions continue to expand.

 By Application

Plasma-derived medicines are essential in managing bleeding disorders like hemophilia A and B, requiring frequent infusion of clotting factor concentrates. Given the chronic nature of these conditions and the need for lifelong treatment, the bleeding disorders segment continues to dominate the plasma-derived medicine market. Alpha-1 Antitrypsin Deficiency a rare genetic disorder that causes lung and liver damage, is increasingly treated with plasma-derived therapies that provide the deficient AAT protein. This growing use of plasma-derived therapies is contributing significantly to the market's expansion. Immunoglobulins, a type of plasma-derived medicine, are used to treat Pelvic Inflammatory Disease (PID), an infection of the female reproductive organs. The increasing awareness and diagnosis of PID are driving demand for these therapies. HAE, a rare condition marked by episodes of severe swelling, is commonly treated with plasma-derived therapies such as C1 esterase inhibitors. This is a key area of market growth, driven by the demand for effective treatments for this rare condition. Plasma-derived medicines are also used in treating various other conditions, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Multifocal Motor Neuropathy (MMN), Liver Disease, and Primary Immune Thrombocytopenia (ITP). As awareness and treatment options expand for these conditions, the demand for plasma-derived therapies in these areas continues to rise.

Segments

Based on Product

• Immunoglobin
• Coagulation Factors,
• Albumin
• Others

Based on Application

• Bleeding Disorders
• Alpha-1 Antitrypsin Deficiency (AATD)
• Pelvic Inflammatory Disease (PID)
• Hereditary Angioedema (HAE)
• Chronic Inflammatory Demyelinating Polyneuropathy
• Guillian=Barre Syndrome
• Multifocal Motor Neuropathy
• Liver Disease
• Primary Immune Thrombocytopenia

Based on Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Others

Based on Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Regional Analysis

North America (45%)

North America holds the largest share of the global plasma-derived medicine market, accounting for approximately 45% of the market share. The region's dominance can be attributed to the advanced healthcare infrastructure, high prevalence of chronic conditions such as bleeding disorders and immunodeficiencies, and a well-established reimbursement system for plasma-derived therapies. The United States is the largest contributor to this region, with a significant number of plasma donation centers and a large patient population requiring regular treatment with immunoglobulins and clotting factors. Additionally, the presence of key market players, such as CSL Behring, Grifols, and Baxter, further strengthens the market in North America. Increasing awareness and early diagnosis of conditions like hemophilia and PID are further fueling the demand for plasma-derived medicines.

Europe (30%)

Europe holds the second-largest share of the global market, contributing about 30%. The region benefits from a strong healthcare system, government initiatives to improve blood plasma collection, and a rising aging population, which is driving demand for plasma-derived treatments. Countries such as Germany, France, and the UK have well-established healthcare systems that ensure widespread access to plasma-derived therapies. The growing prevalence of rare diseases and chronic conditions, including hemophilia and Alpha-1 antitrypsin deficiency (AATD), is increasing the market demand. However, the European market also faces challenges such as varying reimbursement policies across countries and the need for further expansion of plasma collection infrastructure to meet rising demand.

Key players

• Grifols S.A
• CSL Behring
• Takeda Pharmaceuticals
• Octapharma AG
• Kamada Pharmaceuticals

Competitive Analysis

The global plasma-derived medicine market is highly competitive, with leading players such as Grifols S.A., CSL Behring, Takeda Pharmaceuticals, Octapharma AG, and Kamada Pharmaceuticals driving innovation and market growth. Grifols S.A. maintains a strong position in the market, backed by its diverse product portfolio and robust global presence, including its leadership in immunoglobulin and albumin products. CSL Behring is a major competitor with its comprehensive range of therapies for bleeding disorders and immunodeficiencies, known for its high-quality products and innovative research efforts. Takeda Pharmaceuticals has also emerged as a significant player, focusing on rare diseases and expanding its plasma-derived portfolio through acquisitions. Octapharma AG differentiates itself with its focus on immunoglobulin therapies and specialized treatments for coagulation disorders. Kamada Pharmaceuticals leverages its expertise in producing plasma-derived products, particularly for niche applications, strengthening its position in the market. The competition is further driven by continuous R&D, technological advancements, and strategic partnerships.

Recent Developments

• September 2024, CSL Behring received positive reimbursement recommendation for HEMGENIX, a one-time gene therapy for hemophilia B, in Spain.
• In February 2025, Takeda Pharmaceuticals announced efforts to improve plasma availability and streamline manufacturing processes using AI and automation technologies.
• In March 2025, Octapharma AG continued supplying NHS patients with plasma-derived medicines, strengthening supply chain resilience through UK donations.
• In March 2025, Kamada Pharmaceuticals opened a new plasma collection center in San Antonio, Texas, with an annual capacity of 50,000 liters. Plans include FDA and EMA approval submissions later in 2025.

Market Concentration and Characteristics 

The global plasma-derived medicine market is characterized by a moderate level of market concentration, with several large multinational companies dominating the space. Key players such as Grifols S.A., CSL Behring, Takeda Pharmaceuticals, Octapharma AG, and Kamada Pharmaceuticals hold a significant share of the market, benefiting from their extensive product portfolios, strong global distribution networks, and ongoing investments in research and development. Despite the dominance of these players, the market also features smaller companies that focus on specialized therapies or regional markets. The industry is marked by high barriers to entry, including the need for advanced manufacturing capabilities, stringent regulatory requirements, and a reliable plasma supply chain. The market is highly dependent on plasma donation and is driven by increasing demand for treatments related to chronic and rare diseases, which necessitates innovation in product development and treatment options.

Report Coverage

The research report offers an in-depth analysis based on Product, Application, Distribution Channel and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

1. The global plasma-derived medicine market is expected to grow steadily due to rising demand for therapies addressing chronic and rare diseases, with a projected CAGR of 7.00% from 2025 to 2032.
2. Ongoing innovations in plasma collection, fractionation, and purification technologies will drive production efficiency, improving the quality and availability of plasma-derived products.
3. Expanding healthcare infrastructure and increasing awareness in emerging markets, especially in Asia-Pacific and Latin America, will significantly boost the demand for plasma-derived medicines.
4. Personalized medicine will become more prevalent, with plasma-derived therapies being tailored to specific patient profiles, improving efficacy and reducing side effects.
5. The growing adoption of home infusion therapies for conditions like immunodeficiency and bleeding disorders will enhance patient convenience and reduce healthcare costs.
6. Regulatory agencies are likely to streamline approval processes, facilitating quicker access to new plasma-derived therapies, thus supporting market growth.
7. Rising global healthcare spending, particularly in developing economies, will lead to greater access to plasma-derived treatments, improving patient outcomes.
8. Efforts to increase the number of plasma donation centers globally will be essential to meet growing demand, ensuring a sustainable plasma supply chain.
9. Increased investment in research and development will lead to new plasma-derived therapies for previously untreatable conditions, further driving market growth.
10. Strategic acquisitions and partnerships between key players will drive consolidation in the market, fostering the development of innovative plasma-derived products.

Expansion of Healthcare Infrastructure in Emerging Markets

Rapid improvements in healthcare infrastructure and increased healthcare spending in regions such as Asia-Pacific and Latin America are enabling greater access to plasma-derived medicines, driving market growth as more patients and providers adopt advanced therapies.

Advancements in Plasma Collection and Processing Technologies

Innovations such as automated plasma collection systems and improved fractionation techniques have increased plasma yield, enhanced product quality, and reduced costs, making plasma-derived therapies more widely available and reliable.

Increasing Prevalence of Chronic Diseases and Immunodeficiency Disorders

The rising incidence of chronic conditions like hemophilia, autoimmune diseases, and immunodeficiencies is fueling demand for plasma-derived medicines, as these therapies are essential for effective long-term management and improved patient outcomes.

Growing Investment in Research and Development

Pharmaceutical companies are investing heavily in R&D to develop new plasma-derived therapies, expand indications, and improve manufacturing efficiency, resulting in a broader range of treatment options and increased adoption.

Rising Adoption of Home Infusion Therapy

The shift toward home-based administration of plasma-derived therapies, supported by portable infusion devices and patient-centric care models, is increasing treatment convenience and adherence, further expanding the market.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.